GlassScriptPhysician profile
Calvin B Rock
NPI 1679035505
$1,495.28
in general payments reported to CMS, 2019-2025
25 companies · $954 in 2025
The $954 reported for 2025 was more than what 83% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28.76 · 2023: $186 · 2024: $327 · 2025: $954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,466.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $244.12 | 2021-2024 | Spaceoar System, Spaceoar Vue System - 10ml |
| Astrazeneca Pharmaceuticals LP | $173.33 | 2024-2025 | Imfinzi, Lynparza |
| Janssen Biotech, INC. | $131.40 | 2024-2025 | Erleada, Akeega, Talvey |
| Merck Sharp & Dohme LLC | $113.52 | 2024-2025 | Keytruda, Welireg |
| Novartis Pharmaceuticals Corporation | $108.85 | 2024-2025 | |
| Pfizer INC. | $71.10 | 2024-2025 | |
| Daiichi Sankyo INC. | $58.41 | 2024-2025 | Enhertu |
| Abbvie INC. | $55.93 | 2025 | |
| Geron Corporation | $54.73 | 2025 | Rytelo |
| Pharmaessentia USA Corporation | $51.64 | 2025 | Besremi |
| Takeda Pharmaceuticals U.S.A., INC. | $50.29 | 2025 | Iclusig |
| Regeneron Healthcare Solutions, INC. | $45.09 | 2024-2025 | Libtayo |
| Servier Pharmaceuticals LLC | $38.14 | 2025 | |
| Incyte Corporation | $35.43 | 2024-2025 | Jakafi |
| Puma Biotechnology, INC. | $34.15 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $32.99 | 2025 | |
| Genzyme Corporation | $29.85 | 2025 | |
| Elekta, INC. | $27.17 | 2024 | Elekta Medical Linear Accelerator |
| Jazz Pharmaceuticals INC. | $26.98 | 2025 | |
| Sumitomo Pharma America, INC. | $20.23 | 2024 | Orgovyx |
| Genentech USA, INC. | $19.18 | 2024 | Rituxan Hycela, Polivy, Phesgo |
| Exelixis INC. | $18.66 | 2025 | Cabometyx |
| Tolmar, INC. | $18.65 | 2025 | |
| Lilly USA, LLC | $18.17 | 2025 | Jaypirca, Verzenio |
| Azurity Pharmaceuticals, INC. | $17.27 | 2025 | Danziten |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Calvin Rock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.